Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with res...

Prof Georgina Long talks to ecancer about her phase III Checkmate-915 study. An adjuvant trial of nivolumab (NIVO) combined with ipilimumab (IPI) vs the current standard adjuvant treatment, nivolumab alone, in patients with resected stage III B, C, D & stage IV melanoma.
Prof Long begins by giving some background to the trial stating what is known so far about the efficacy of both NIVO and IPI in comparison with each other and in the case of IPI, compared with placebo.
She then goes on to talk about the methodology used and how the results showed that there wasn't much of a benefit for using both NIVO and IPI together, compared to NIVO alone.
To conclude, Prof Long talks about how after this phase in the trial NIVO remains a standard for anti-PD1 therapy along with pembrolizumab for resected stage III melanoma, and NIVO alone for resected stage IV melanoma.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php